HighTide Therapeutics Inc (2511.HK)

Healthcare | Biotechnology
Income Statement (Quarterly) 2026-04-08 2025-06-30 2025-03-31 2024-12-31
Revenue 0 0 0 0
Cost of Revenue 0 0 0 0
Gross Profit 0 0 0 0
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 21,624 21,624 10,812 17,587
Operating Expenses 128,038 128,038 64,019 98,363
Operating Income -128,039 -128,039 -64,020 -98,363
Interest Expense 0 0 0 0
Income Before Tax -113,851 -113,851 -56,926 -85,556
Income Tax Expense 6 6 3 135
Net Income -120,317 -120,317 -60,159 -85,422
Per Share
EPS -0.26 -0.26 -0.13 -0.19
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2024-12-31 2023-12-31
Revenue 0 0
Cost of Revenue 0 1,830,196
Gross Profit 0 -1,830,197
Operating Expenses
R&D Expenses 0 0
SG&A Expenses 81,229 136,670,000
Operating Expenses 444,754 438,336,000
Operating Income -444,754 -440,357,041
Interest Expense 0 400,000
Income Before Tax -381,519 -939,230,000
Income Tax Expense 269 76,000
Net Income -381,788 -939,306,000
Per Share
EPS -0.84 -2.02
EPS Diluted 0.00 0.00
Balance Sheet (Quarterly) 2024-12-31 2023-12-31
Assets
Cash and Cash Equivalents 310,750,000 608,212,000
Short Term Investments 179,772,000 127,489,000
Net Receivables 295,000 0
Inventory 0 0
Total Current Assets 513,371,000 778,753,000
Property Plant Equipment 23,891,000 14,981,000
Goodwill and Intangibles 0 0
Total Assets 559,931,000 795,036,000
Liabilities
Account Payables 51,473,000 30,507,000
Short Term Debt 52,419,000 5,968,000
Total Current Liabilities 109,946,000 79,811,000
Long Term Debt 25,486,000 10,464,000
Total Liabilities 135,763,000 92,262,000
Shareholders Equity
Retained Earnings 0 636,122,272
Total Shareholders Equity 424,168,000 702,774,000
Balance Sheet (Annual) 2024-12-31 2023-12-31
Assets
Cash and Cash Equivalents 310,750,000 608,212,000
Short Term Investments 179,772,000 127,489,000
Net Receivables 295,000 0
Inventory 0 0
Total Current Assets 513,371,000 778,753,000
Property Plant Equipment 23,891,000 14,981,000
Goodwill and Intangibles 0 0
Total Assets 559,931,000 795,036,000
Liabilities
Account Payables 51,473,000 30,507,000
Short Term Debt 52,419,000 5,968,000
Total Current Liabilities 109,946,000 79,811,000
Long Term Debt 25,486,000 10,464,000
Total Liabilities 135,763,000 92,262,000
Shareholders Equity
Retained Earnings 0 636,122,272
Total Shareholders Equity 424,168,000 702,774,000
Cash Flow Statement (Quarterly) 2024-12-31 2023-12-31
Operating Activities
Net Income -381,788,000 -939,230,000
Depreciation & Amortization 0 1,829,000
Stock Based Compensation 96,932,000 93,493,000
Change in Working Capital 3,939,000 -12,781,000
Operating Cash Flow -298,466,000 -357,919,000
Investing Activities
Capital Expenditure -4,285,000 -801,000
Investments 0 -801,000
Investing Cash Flow -54,660,000 316,658,000
Financing Activities
Debt Repayment 53,389,000 -4,650,000
Common Stock Issued/Repurchased 0 252,895,000
Dividends Paid 0 0
Financing Cash Flow 0 361,103,000
Summary
Free Cash Flow -302,751,000 -358,720,000
Net Change in Cash -297,462,000 335,165,000
Cash Flow Statement (Annual) 2024-12-31 2023-12-31
Operating Activities
Net Income -381,788,000 -939,230,000
Depreciation & Amortization 0 1,829,000
Stock Based Compensation 96,932,000 93,493,000
Change in Working Capital 3,939,000 -12,781,000
Operating Cash Flow -298,466,000 -357,919,000
Investing Activities
Capital Expenditure -4,285,000 -801,000
Investments 0 -801,000
Investing Cash Flow -54,660,000 316,658,000
Financing Activities
Debt Repayment 53,389,000 -4,650,000
Common Stock Issued/Repurchased 0 252,895,000
Dividends Paid 0 0
Financing Cash Flow 0 361,103,000
Summary
Free Cash Flow -302,751,000 -358,720,000
Net Change in Cash -297,462,000 335,165,000